Science Corp. Raises $230 Million To Advance Brain-Computer Interface Implant For Vision Restoration
Science Corporation, a brain-computer interface startup founded by former Neuralink president Max Hodak, said Wednesday it has raised $230 million in a Series ...
Beijing is gearing up to bring brain-computer interface (BCI) technology into everyday use within the next three to five ...
China is advancing rapidly in brain-computer interface (BCI) technology, aiming to implement practical products in three to five years. In its new strategic plan, Beijing prioritizes BCIs alongside ...
China's BCI market estimated to reach $809 million by 2027 China expanding clinical trials, state support for BCIs Aims to close gap between research, industry and clinic BEIJING, March 8 (Reuters) - ...
Science Corp., a developer of brain-computer interfaces and other medical equipment, today announced that it has raised $230 million in funding. The capital came from a consortium that included ...
Science Corp., a biotech startup focused on brain-computer interface technologies, announced Thursday that it has closed on a ...
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and ...
No one has had a Synchron brain-computer interface longer than Rodney Gorham. He’s still finding new ways to use it.
Chinese company Gestala develops non-invasive ultrasound brain-computer interfaces as alternative to surgical implants, ...
China initiated its first multi-center clinical trial for brain-computer interface technology in neurocritical care on Sunday, marking a significant expansion of BCI applications beyond the ...
Medical Device Network on MSN
Neurosoft gains BCI ecosystem access in partnership first with Science Corporation
Science’s brain computer interface (BCI) ecosystem is a neural data platform designed to simplify partners’ development of BCI technologies.
China’s brain-computer interface industry is rapidly scaling from research to commercialization, driven by strong policy support, expanding clinical trials, and growing investor interest.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results